972-20-3

Basic information

• Product Name: 1-benzyl-4-[(4-chlorophenyl)amino]piperidine-4-carbonitrile
• Synonyms: 1-benzyl-4-[(4-chlorophenyl)amino]piperidine-4-carbonitrile;1-Benzyl-4-[(4-chlorophenyl)amino]-4-piperidinecarbonitrile;1-BENZYL-4-(4-CHLOROANILINO)-4-CYANOPIPERIDINE
• CAS NO: 972-20-3
• Molecular Formula: C₁₉H₂₀ClN₃
• Molecular Weight: 325.8352
• EINECS: 213-545-6
• Mol File: 972-20-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 508.7°Cat760mmHg
• Flash Point: 261.4°C
• Appearance: /
• Density: 1.22g/cm³
• Vapor Pressure: 1.82E-10mmHg at 25°C
• Refractive Index: 1.628
• CAS DataBase Reference: 1-benzyl-4-[(4-chlorophenyl)amino]piperidine-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-4-[(4-chlorophenyl)amino]piperidine-4-carbonitrile(972-20-3)
• EPA Substance Registry System: 1-benzyl-4-[(4-chlorophenyl)amino]piperidine-4-carbonitrile(972-20-3)

Safety Data

• Hazardous Substances Data: 972-20-3(Hazardous Substances Data)

Usage

Molecular structure

1-benzyl-4-[(4-chlorophenyl)amino]piperidine-4-carbonitrile has a complex molecular structure that includes a piperidine ring, a benzyl group, a chlorophenylamino group, and a carbonitrile group.

Chemical class

It belongs to the class of piperidine derivatives, which are organic compounds that contain a six-membered nitrogen-containing ring.

Functional groups

The compound contains three main functional groups a benzyl group (C6H5-CH2-), a chlorophenylamino group (Cl-C6H4-NH-), and a carbonitrile group (-CN).

Potential applications

1-benzyl-4-[(4-chlorophenyl)amino]piperidine-4-carbonitrile may have potential applications in pharmaceutical research and development, particularly in the development of new medications for various medical conditions.

Further investigation

The specific properties and potential uses of 1-benzyl-4-[(4-chlorophenyl)amino]piperidine-4-carbonitrile would require further scientific investigation and analysis to be fully understood and utilized.

InChI:InChI=1/C19H20ClN3/c20-17-6-8-18(9-7-17)22-19(15-21)10-12-23(13-11-19)14-16-4-2-1-3-5-16/h1-9,22H,10-14H2

Upstream product

• 1336-21-6 ammonium hydroxide 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 7677-24-9 trimethylsilyl cyanide 
• 106-47-8 4-chloro-aniline 

Downstream Products

• 1045-51-8 1-benzyl-4-(4-chloro-phenylamino)-piperidine-4-carboxylic acid amide 
• 1039366-72-7 4-(4-chloro-phenylamino)-piperidine-4-carbonitrile 
• 849106-07-6 1-benzyl-4-(4-chloro-phenylamino)-piperidine-4-carboxylic acid methyl ester 
• 976-96-5 8-benzyl-1-(4-chlorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one 
• 227029-23-4 8-benzyl-1-(4-chlorophenyl)-1,3,8-triazaspiro[4.5]dec-2-en-4-one 

Relevant articles and documents

1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY

The present invention relates to a 1,3,8-triazaspiro compound of Formula (I), wherein A is -CH2, -SO2 -, -NH-CO-, -NH-CS- or -CO-; the dashed line represents a single or double bond; R1 is a substituent selected from (C1-C3) alkyl, phenyl, thienyl and cyclohexyl, said substituent being optionally substituted by halogen or (C1 -C3) alkyl; and R2 is a substituent selected from H, (C1-C3) alkyl, (C1-C3) alkoxy, -CF3 and halogen; and wherein, when the dashed line is a double bond, A is -CH2 - and R1 is phenyl, or a pharmaceutically acceptable salt thereof for use in the treatment of reperfusion injury diseases. The 1,3,8-triazaspiro compound of the invention is a selective inhibitor of the C subunit of the F1/Fo-ATP synthase complex and a modulator of the mitochondrial permeability transition pore activity in mammalian cells and tissues, in the treatment of reperfusion injury diseases.

CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

Chemokine receptor antagonists and methods of use thereof

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.